神经损伤与功能重建Issue(3)：214-215,250,3.DOI:10.3870/sjsscj.2014.03.012
重组组织型纤溶酶原激活剂静脉溶栓治疗房颤急性缺血性卒中的临床研究
Thrombolytic Therapy with Intravenous Recombinant Tissue-type Plasminogen Activator for Acute Ischemic Stroke Patients with Atrial Fibrillation
余勇飞 1贾复敏 1魏衡 1张丽 1阮清源 1宋林 1尹虹祥 1周瑞 1许康1
作者信息
- 1. 湖北省新华医院神经内科武汉 430015
- 折叠
摘要
Abstract
Objective To investigate the safety and efficacy of thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke of patients with or without atrial fibrillation(AF). Methods: Consecutive acute ischemic stroke patients (n=61) treated with intravenous rt-PA with-in 4.5 h after stroke onset were studied. The patients were divided into groups AF (n=22) and Non-AF(n=39). The clinical characteristics of the two groups were compared. NIHSS and mRS were used to assess the efficacy and safety before thrombolysis and 2 h, 24 h, 7 d, 90 d respectively after thrombolysis. Results: The percentage of males and the median time for the administration of rt-PA were lower in the AF group then those in the Non-AF group ( <0.05). The prime SBP was higher in the AF group than that in the Non-AF group. There were no significant differences in the NIHSS at 2 h, 24 h, and 7 d, the efficacy at 7 d, and the mRS at 90 d after thrombolysis between the two groups. Conclusion: There were no significant differences in the safety and efficacy of thrombolytic therapy with rt-PA in treating acute ischemic stroke of patients with or without AF.关键词
重组组织型纤溶酶原激活剂/急性缺血性卒中/静脉溶栓/心房颤动Key words
recombinant tissue-type plasminogen activator/acute ischemic stroke/thrombolysis/atrial fibrilla-tion分类
医药卫生引用本文复制引用
余勇飞,贾复敏,魏衡,张丽,阮清源,宋林,尹虹祥,周瑞,许康..重组组织型纤溶酶原激活剂静脉溶栓治疗房颤急性缺血性卒中的临床研究[J].神经损伤与功能重建,2014,(3):214-215,250,3.
